Avalo Therapeutics (AVTX) EBT (2014 - 2026)
Avalo Therapeutics (AVTX) posted EBT of -$19.6 million for Q1 2026, down 44.36% on a QoQ basis from -$13.6 million in Q4 2025, and down 49.29% year-over-year from -$38.7 million in Q1 2025.
Avalo Therapeutics (AVTX) EBT (2014 - 2026) Analysis & Trends
Avalo Therapeutics' EBT history runs 13 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- Quarterly EBT fell 49.29% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.6 million (down 215.65% YoY) and the FY2025 annual result came in at -$78.1 million, down 123.03% from the prior year.
- EBT was -$19.6 million for Q1 2026 at Avalo Therapeutics, down from -$13.6 million in the prior quarter.
- Across five years, EBT topped out at $98.5 million in Q2 2024 and bottomed at -$121.3 million in Q1 2024.
- A 5-year average of -$12.1 million and a median of -$13.0 million in 2022 frame the typical range for EBT.
- Peak annual rise in EBT reached 1302.91% in 2024, while the deepest fall reached 1119.29% in 2024.
- Avalo Therapeutics' EBT stood at -$9.8 million in 2022, then grew by 16.6% to -$8.2 million in 2023, then plunged by 330.78% to -$35.2 million in 2024, then jumped by 61.42% to -$13.6 million in 2025, then plunged by 44.36% to -$19.6 million in 2026.
- Business Quant data shows AVTX's EBT at -$19.6 million in Q1 2026, -$13.6 million in Q4 2025, and -$30.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -19.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.62 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -20.75 Mn |
| Mar 31, 2025 | -13.14 Mn |
| Dec 31, 2024 | -35.23 Mn |
| Sep 30, 2024 | 23.02 Mn |
| Jun 30, 2024 | 98.47 Mn |
| Mar 31, 2024 | -121.28 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.95 Mn |
| Dec 31, 2022 | -9.80 Mn |
| Sep 30, 2022 | 3.20 Mn |
| Jun 30, 2022 | -12.98 Mn |
| Mar 31, 2022 | -22.04 Mn |
| Dec 31, 2021 | -19.15 Mn |
| Sep 30, 2021 | -17.46 Mn |
| Jun 30, 2021 | -17.37 Mn |